BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Biogen Bets on Anticipated Approvals Amidst Pipeline Reprioritization

  During its Q1 earnings call Tuesday, Biogen announced a handful of program pauses and cuts and touted the potential of anticipated approvals.

  April 26, 2023

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Policy

  US Senate Kicks Off Fresh Round of Drug Pricing Control Legislation

  The proposed drug pricing legislations follow the Inflation Reduction Act, passed in August 2022.

  April 26, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

  Novartis is scaling back its pipeline to focus on higher-value assets with stronger commercial potential.

  April 26, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Beam Spin-Out Orbital Therapeutics Raises $270M to Advance RNA Portfolio

  Orbital will use Series A funds to advance RNA-based vaccines, immunomodulators and protein replacement therapies.

  April 26, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Drug Development

  Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study

  Alentis Therapeutics announced results from the multiple-ascending dose part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1.

  April 26, 2023

   · 

  2 min read
• Job Trends

  Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

  Sanofi announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.

  April 26, 2023

   · 

  7 min read
• Pharm Country

  Huma and UCB partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

  Huma Therapeutics and UCB are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis, better understand and manage their condition with the support of their clinician.

  April 26, 2023

   · 

  4 min read
• Business

  BioInvent International AB: Interim Report January-March 2023

  After the end of the quarter, we received very positive news in our BI-1206 project.

  April 26, 2023

   · 

  2 min read
• Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023

  Nicox SA announced that the transfer of the listing of the securities issued by the Company from the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading facility, will be effective as from the trading session of April 28, 2023.

  April 26, 2023

   · 

  4 min read
• Business

  Thermo Fisher Scientific Reports First Quarter 2023 Results

  Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended April 1, 2023.

  April 26, 2023

   · 

  10 min read